Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
Scope of the Report:
This report focuses on the Chemotherapy-induced Nausea and Vomiting Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
North America is the largest sales region of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs
The worldwide market for Chemotherapy-induced Nausea and Vomiting Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017.
Market Segment by Manufacturers, this report covers
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck & Co
- Tesaro
- Acacia Pharma
- Aphios
- Barr Laboratories
- Baxter Healthcare
- Eisai
- Especificos Stendhal
- F.Hoffmann La Roche
- Mundipharma
- Mylan Pharmaceuticals
- OPKO Health
- Orchid Healthcare
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Aloxi (palonosetron)
- Kytril Generic (granisetron)
- Emend (aprepitant)
- Akynzeo (netupitant-palonosetron)
Market Segment by Applications, can be divided into
- Blood Cancer
- Breast Cancer
- Gastrointestinal Tract Cancer
- Others
There are 15 Chapters to deeply display the global Chemotherapy-induced Nausea and Vomiting Drugs market.
Chapter 1, to describe Chemotherapy-induced Nausea and Vomiting Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Chemotherapy-induced Nausea and Vomiting Drugs, with sales, revenue, and price of Chemotherapy-induced Nausea and Vomiting Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Chemotherapy-induced Nausea and Vomiting Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Chemotherapy-induced Nausea and Vomiting Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Chemotherapy-induced Nausea and Vomiting Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source